Oliver H. Tam

Oliver H. Tam

Auto-generated profile, based on publicly available information

Oliver H. Tam

Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, MD, 20815, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2008 in Nature
Verified
Journal Article
Closed access
PDF file
OTOliver H. Tam
Oliver H. Tam
AAAlexei A. Aravin
Alexei A. Aravin
PSPaula Stein
Paula Stein
AGAngelique Girard
Angelique Girard
EMElizabeth P. Murchison
Elizabeth P. Murchison
GHGregory J. Hannon
Gregory J. Hannon

23 July 2015 in Bioinformatics
Verified
Journal Article
Open access
PDF file
YJYing Jin
Ying Jin
OTOliver H. Tam
Oliver H. Tam
EPEric Paniagua
Eric Paniagua
MHMolly Gale Hammell
Molly Gale Hammell
Motivation: Most RNA-seq data analysis software packages are not designed to handle the complexities involved in properly apportioning short sequencing reads to highly repetitive regions of the genome. These regions are often occupied by transposable elements (TEs), which make up between 20 and 80% of eukaryotic genomes. They can contribute a substantial portion of transcriptomic and genomic sequence reads, but are typically ignored in most analyses. Results: Here, we present a method and software package for including both gene- and TE-associated ambiguously mapped reads in differential expression analysis. Our method shows improved recovery of TE transcripts over other published expression analysis methods, in both synthetic data and qPCR/NanoString-validated published datasets. Availability and implementation: The source code, associated GTF files for TE annotation, and testing data are freely available at http://hammelllab.labsites.cshl.edu/software. Contact:mhammell@cshl.edu. Supplementary information: Supplementary data are available at Bioinformatics online.

1 October 2019 in Cell Reports
Verified
Journal Article
Open access
OTOliver H. Tam
Oliver H. Tam
NRNikolay V. Rozhkov
Nikolay V. Rozhkov
RSRegina Shaw
Regina Shaw
DKDuyang Kim
Duyang Kim
IHIsabel Hubbard
Isabel Hubbard
MHMolly Gale Hammell
Molly Gale Hammell
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the progressive loss of motor neurons. While several pathogenic mutations have been identified, the vast majority of ALS cases have no family history of disease. Thus, for most ALS cases, the disease may be a product of multiple pathways contributing to varying degrees in each patient. Using machine learning algorithms, we stratify the transcriptomes of 148 ALS postmortem cortex samples into three distinct molecular subtypes. The largest cluster, identified in 61% of patient samples, displays hallmarks of oxidative and proteotoxic stress. Another 19% of the samples shows predominant signatures of glial activation. Finally, a third group (20%) exhibits high levels of retrotransposon expression and signatures of TARDBP/TDP-43 dysfunction. We further demonstrate that TDP-43 (1) directly binds a subset of retrotransposon transcripts and contributes to their silencing in vitro, and (2) pathological TDP-43 aggregation correlates with retrotransposon de-silencing in vivo.

1 October 2014 in Seminars in Cell & Developmental Biology
Verified
Journal Article
Closed access
YKYoji Kojima
Yoji Kojima
OTOliver H. Tam
Oliver H. Tam
PTPatrick Tam
Patrick Tam

23 September 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
KTKen Tajima
Ken Tajima
TYToshifumi Yae
Toshifumi Yae
SJSarah Javaid
Sarah Javaid
OTOliver Tam
Oliver Tam
VCValentine Comaills
Valentine Comaills
SMShyamala Maheswaran
Shyamala Maheswaran
Expression of the p53-inducible antiproliferative gene BTG2 is suppressed in many cancers in the absence of inactivating gene mutations, suggesting alternative mechanisms of silencing. Using a shRNA screen targeting 43 histone lysine methyltransferases (KMTs), we show that SETD1A suppresses BTG2 expression through its induction of several BTG2-targeting miRNAs. This indirect but highly specific mechanism, by which a chromatin regulator that mediates transcriptional activating marks can lead to the downregulation of a critical effector gene, is shared with multiple genes in the p53 pathway. Through such miRNA-dependent effects, SETD1A regulates cell cycle progression in vitro and modulates tumorigenesis in mouse xenograft models. Together, these observations help explain the remarkably specific genetic consequences associated with alterations in generic chromatin modulators in cancer.

24 July 2015 in The Plant Cell
Verified
Journal Article
Closed access
PDF file
KPKatherine Petsch
Katherine Petsch
PMPriscilla S. Manzotti
Priscilla S. Manzotti
OTOliver H. Tam
Oliver H. Tam
RMRobert Meeley
Robert Meeley
MHMolly Gale Hammell
Molly Gale Hammell
MTMarja C.P. Timmermans
Marja C.P. Timmermans
Dicer enzymes function at the core of RNA silencing to defend against exogenous RNA or to regulate endogenous genes. Plant DICER-LIKE4 (DCL4) performs dual functions, acting in antiviral defense and in development via the biogenesis of trans-acting short-interfering RNAs (siRNAs) termed tasiR-ARFs. These small RNAs play an essential role in the grasses, spatially defining the expression domain of AUXIN RESPONSE FACTOR3 (ARF3) transcription factors. However, contrary to tasiR-ARFs’ essential function in development, DCL4 proteins exhibit strong evidence of recurrent adaptation typical of host factors involved in antiviral immunity. Here, we address how DCL4 balances its role in development with pressures to diversify in response to viral attack. We show that, in contrast to other tasiR-ARF biogenesis mutants, dcl4 null alleles have an uncharacteristically mild phenotype, correlated with normal expression of select arf3 targets. Loss of DCL4 activity yields a class of 22-nucleotide tasiR-ARF variants associated with the processing of arf3 transcripts into 22-nucleotide secondary siRNAs by DCL1. Our findings reveal a DCL1-dependent siRNA pathway that bypasses the otherwise adverse developmental effects of mutations in DCL4. This pathway is predicted to have important implications for DCL4’s role in antiviral defense by reducing the selective constraints on DCL4 and allowing it to diversify in response to viral suppressors.